Duloxetine Capsule, Delayed Release
Product Images NDC 71335-1964

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-1964). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Image 01)

A line graph comparing the proportion of patients with relapse over time between Duloxetine treatment and placebo. The x-axis represents time up to approximately 250 units, and the y-axis shows the proportion of patients with relapse ranging from 0.0 to 1.0. The Duloxetine group shows a lower proportion of relapse compared to the placebo group throughout the observed period.*

FDA Label Image

Image 2 (Image 02)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time from randomization to relapse (days) between Duloxetine and placebo treatments. The graph shows relapse proportions on the y-axis (0.0 to 1.0) and time in days on the x-axis (0 to 300). Two treatment groups are differentiated by line style: Duloxetine (solid line) and placebo (dashed line).*

FDA Label Image

Image 3 (Image 03)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine and placebo groups. The graph compares Duloxetine 60 mg twice daily, 60 mg once daily, 20 mg once daily, and placebo, illustrating patient response across a range of pain improvement percentages.*

FDA Label Image

Image 4 (Image 04)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph illustrates that both Duloxetine groups have higher percentages of patients improved across pain improvement levels compared to placebo.*

FDA Label Image

Image 5 (Image 05)

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline. Three lines represent duloxetine 60 mg twice daily, duloxetine 60 mg once daily, and placebo, showing comparative trends in pain improvement over the measured range.*

FDA Label Image

Image 6 (Image 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses of 120 mg, 60 mg, 20 mg once daily, and placebo. Lines show decreasing patient improvement percentages as pain improvement thresholds increase, with placebo consistently lower than Duloxetine doses.*

FDA Label Image

Image 7 (Image 07)

A line graph comparing the percentage of patients improved at various levels of percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement thresholds from >0 to 100%, and the y-axis shows the percentage of patients improved, from 0% to 100%. The graph illustrates higher patient improvement percentages with Duloxetine across most pain improvement levels compared to placebo.*

FDA Label Image

Image 8 (Image 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two data series are shown: Placebo and Duloxetine 60 mg once daily, with Duloxetine consistently showing higher patient improvement percentages across varying levels of pain improvement.*

FDA Label Image

Image 9 (Image 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows percent improvement in pain. Duloxetine shows a higher percentage of patient improvement across most pain improvement levels compared to placebo.*

FDA Label Image

Label (Lbl713351964)

Label for Duloxetine HCL delayed release 20 mg capsules, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares this product to Cymbalta 20 mg capsules by Zhejiang Huahai Pharma Co., Ltd. It includes warnings for potential drowsiness, storage instructions at 20°-25°C (68°-77°F), and shows an NDC number of 71335-1964-1. The package size is 30 capsules.*

FDA Label Image

Chemical Structure (Structure)

Chemical structure of duloxetine hydrochloride, the active ingredient in DULOXETINE capsules, delayed release 20 mg, by Bryant Ranch Prepack. The structure includes a thiophene ring, a naphthalene group, and an amine hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.